Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors, particularly in targeted cancer therapies. Its structure enables selective binding to mutant forms of EGFR, making it valuable in the development of anticancer drugs, especially for non-small cell lung cancer (NSCLC). The compound's nitro and chloro functional groups facilitate further chemical modifications, allowing optimization of pharmacokinetic properties in drug design. It is primarily employed in research and pharmaceutical development rather than direct therapeutic use.